Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Gynecologic Oncology

• Publication date

  2009-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ygyno.2009.09.011PMID 19811811PMCID PMC2783261
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.

  2009cited by this paper
• Phase II study of sunitinib malate (SM) in subjects with metastatic and/or surgically unresectable non-GIST soft tissue sarcomas

  2008cited by this paper
• Continuous daily dosing (CDD) of sunitinib (SU) in patients with metastatic soft tissue sarcomas (STS) other than GIST: Results of a phase II trial

  2008cited by this paper
• Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial.

  2008cited by this paper
• A Method for Utilizing Bivariate Efficacy Outcome Measures to Screen Agents for Activity in 2-Stage Phase II Clinical Trials

  2008cited by this paper
• Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.

  2008cited by this paper
• A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study.

  2007cited by this paper
• Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.

  2006cited by this paper
• Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.

  2006cited by this paper
• Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study.

  2005cited by this paper
• Safety and pharmacokinetics of intravenous VEGF Trap in a phase I clinical trial of patients with advanced solid tumors

  2005cited by this paper
• Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study.

  2004influential reference
• Evaluation of paclitaxel in previously treated leiomyosarcoma of the uterus: a gynecologic oncology group study.

  2003cited by this paper
• Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas.

  2002cited by this paper
• Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.

  2002cited by this paper
• VEGF-Trap: A VEGF blocker with potent antitumor effects

  2002cited by this paper
• Trimetrexate in the treatment of recurrent or advanced leiomyosarcoma of the uterus: a phase II study of the Gynecologic Oncology Group.

  2002cited by this paper
• Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity.

  2001cited by this paper
• Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: a Gynecologic Oncology Group Study.

  2000cited by this paper
• Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival.

  1999cited by this paper
• Amonafide in patients with leiomyosarcoma of the uterus: a phase II Gynecologic Oncology Group study.

  1998cited by this paper
• Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: a gynecologic oncology group study.

  1998cited by this paper
• Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in endometrial carcinoma

  1996cited by this paper
• Phase II trial of paclitaxel in leiomyosarcoma of the uterus: a gynecologic oncology group study.

  1996cited by this paper
• Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study.

  1996cited by this paper
• Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia.

  1995cited by this paper
• Vascular permeability factor gene expression in normal and neoplastic human ovaries.

  1994cited by this paper
• Prognostic factors in early‐stage uterine sarcoma: A gynecologic oncology group study

  1993cited by this paper
• Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.

  1992cited by this paper
• Phase II trial of ifosfamide and mesna in leiomyosarcoma ofthe uterus: A Gynecologic Oncology Group study

  1992cited by this paper
• A phase II clinical trial of diaziquone (AZQ) in the treatment of patients with recurrent leiomyosarcoma of the uterus

  1991cited by this paper
• Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study.

  1991cited by this paper
• Mitoxantrone in the Treatment of Advanced Uterine Sarcoma: A Phase II Trial of the Gynecologic Oncology Group

  1990cited by this paper
• Phase II trial of etoposide in the management of advanced and recurrent leiomyosarcoma of the uterus: a Gynecologic Oncology Group Study.

  1987cited by this paper
• [New drugs. 9].

  1973cited by this paper

• Loss of the DNA Repair Gene RNase H2 Identifies a Unique Subset of DDR-Deficient Leiomyosarcomas.

  2024cites this paper
• A Ten-Year Real-Life Experience with Pazopanib in Uterine Leyomiosarcoma in Two High-Specialized Centers in Italy: Effectiveness and Safety

  2023cites this paper
• Efficacy and safety of apatinib in patients with recurrent uterine malignancy: a prospective, single-center, single-arm, phase 2 study

  2023cites this paper
• Evaluation of the efficacy of systemic therapy for advanced uterine leiomyosarcoma: A systematic review, meta‐analysis, and meta‐regression analysis

  2023cites this paper
• The GOG Foundation, Inc. Uterine Cancer Trials

  2023cites this paper
• The Role of AKT in Soft Tissue Sarcoma: Review and Insights.

  2022cites this paper
• Status of the Current Treatment Options and Potential Future Targets in Uterine Leiomyosarcoma: A Review

  2022cites this paper
• Regorafenib for the Treatment of Sarcoma

  2022cites this paper
• Efficacy thresholds for clinical trials with advanced or metastatic leiomyosarcoma patients: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group meta-analysis based on a literature review for soft-tissue sarcomas.

  2021cites this paper
• Apatinib as targeted therapy for advanced bone and soft tissue sarcoma: a dilemma of reversing multidrug resistance while suffering drug resistance itself

  2020cites this paper
• This is a repository copy of A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in high-grade uterine sarcoma after stabilization or response to doxorubicin ± ifosfamide following surgery or in metastatic first line

  2020cites this paper
• Systemic treatment in adult uterine sarcomas

  2019influential citation
• Current state of the art and emerging pharmacotherapy for uterine leiomyosarcomas

  2019cites this paper
• Uterine sarcoma diagnose and treatment: review article

  2018cites this paper
• Treatment-related adverse effects with pazopanib, sorafenib and sunitinib in patients with advanced soft tissue sarcoma: a pooled analysis

  2018cites this paper
• Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcoma.

  2018cites this paper
• Systemic treatment in adult uterine sarcomas.

  2018cites this paper
• Androgen receptor as a prognostic biomarker and therapeutic target in uterine leiomyosarcoma

  2018cites this paper
• Systemic Treatment of Metastatic/Recurrent Uterine Leiomyosarcoma: A Changing Paradigm.

  2018cites this paper
• Newer medical therapies for metastatic soft tissue sarcoma

  2017cites this paper
• A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D.

  2017cites this paper
• Uterine leiomyosarcoma: Epidemiology, contemporary treatment strategies and the impact of uterine morcellation.

  2017cites this paper
• Uterine sarcoma – current perspectives

  2017cites this paper
• Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new

  2017cites this paper
• Uterine Sarcoma: Modern Treatment Paradigms

  2017cites this paper
• Geriatric Cardio-oncology

  2017cites this paper
• Targeted Therapy in Gynecological Malignancy

  2017cites this paper
• The Value of Anti-Angiogenics in Soft Tissue Sarcoma Therapy

  2017cites this paper
• Nonendometrioid Endometrial Carcinomas and Uterine Sarcomas

  2017cites this paper
• Curative effect of bevacizumab combined with chemotherapy in advanced or recurrent uterine sarcoma.

  2016cites this paper
• Management of Uterine Sarcomas

  2016cites this paper
• Combination of cytotoxic agents and targeted therapy for the treatment of advanced sarcomas: preclinical background and early clinical development

  2016cites this paper
• Current Chemotherapy and Potential New Targets in Uterine Leiomyosarcoma

  2016influential citation
• Uterine sarcoma Part I-Uterine leiomyosarcoma: The Topic Advisory Group systematic review.

  2016cites this paper
• The role of adjuvant therapy in uterine leiomyosarcoma

  2016cites this paper
• Pazopanib in the management of advanced soft tissue sarcomas

  2016cites this paper
• Uterine sarcoma Part II-Uterine endometrial stromal sarcoma: The TAG systematic review.

  2016cites this paper
• Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072.

  2016cites this paper
• Uterine sarcoma part III-Targeted therapy: The Taiwan Association of Gynecology (TAG) systematic review.

  2016cites this paper
• Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib.

  2016cites this paper
• Histology-Specific Uses of Tyrosine Kinase Inhibitors in Non-gastrointestinal Stromal Tumor Sarcomas

  2016cites this paper
• Targeted therapy and promising novel agents for the treatment of advanced soft tissue sarcomas

  2015cites this paper
• Microvessels Density in Uterine Leiomyosarcoma

  2015cites this paper
• Potential Therapeutic Targets in Uterine Sarcomas

  2015cites this paper
• Antiangiogenic agents in gynecological cancer: State of art and perspectives of clinical research.

  2015cites this paper
• Management Strategies in Advanced Uterine Leiomyosarcoma: Focus on Trabectedin

  2015cites this paper
• Pharmacological treatment for uterine leiomyosarcomas

  2015cites this paper
• Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study.

  2015cites this paper
• Targeted therapy in sarcomas other than GIST tumors

  2015cites this paper
• Risk assessment of radio-chemotherapy in pediatric soft tissue sarcomas

  2015cites this paper
• An investigation into tetraspanin CD151 as novel prognostic markers in poor outcome endometrial cancer

  2014cites this paper
• The angiogenic asset of soft tissue sarcomas: a new tool to discover new therapeutic targets

  2014cites this paper
• Tumour angiogenesis in Epstein-Barr virus-associated post-transplant smooth muscle tumours

  2014cites this paper
• Feasibility study of gemcitabine plus docetaxel in advanced or recurrent uterine leiomyosarcoma and undifferentiated endometrial sarcoma in Japan

  2014cites this paper
• Management of uterine sarcoma

  2014cites this paper
• Management of advanced uterine leiomyosarcoma

  2014cites this paper
• Systemic treatment of soft-tissue sarcoma—gold standard and novel therapies

  2014cites this paper
• Do anti-angiogenic cancer therapies increase risk of significant weight loss?

  2014cites this paper
• Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta‐analysis of 36 clinical trials

  2014cites this paper
• Anti-angiogenic therapy, a new player in the field of sarcoma treatment.

  2014influential citation
• Advances in the diagnosis and treatment of uterine sarcomas.

  2014cites this paper
• Sorafenib plus dacarbazine in solid tumors: a phase I study with dynamic contrast-enhanced ultrasonography and genomic analysis of sequential tumor biopsy samples

  2014cites this paper
• Recent advances in the treatment of sarcomas in gynecology.

  2014cites this paper
• Anti-angiogenic drugs currently in Phase II clinical trials for gynecological cancer treatment

  2013cites this paper
• Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide

  2013cites this paper
• Management of sarcomas of the uterus

  2013cites this paper
• Risk of hematologic toxicities in cancer patients treated with sunitinib: a systematic review and meta-analysis.

  2013cites this paper
• Treatment options for leiomyosarcoma

  2013cites this paper
• The biology of uterine sarcomas: A review and update

  2013cites this paper
• [Uterine leiomyosarcoma: epidemiology, pathology, biology, diagnosis, prognosis and treatment].

  2013cites this paper
• Antiangiogenic approach in soft-tissue sarcomas

  2013cites this paper
• New drugs and combinations for the treatment of soft-tissue sarcoma: a review

  2012cites this paper
• A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia.

  2012cites this paper
• Novel targets for VEGF-independent anti-angiogenic drugs

  2012cites this paper
• Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen.

  2012cites this paper
• The treatment of uterine sarcomas.

  2012cites this paper
• Uterine carcinosarcoma, leiomyosarcoma and endometrial stromal sarcoma : Epidemiological, clinical and prognostic aspects

  2012cites this paper
• Uterine sarcomas: histology and its implications on therapy.

  2012cites this paper
• Targeting angiogenesis in gynecologic cancers.

  2012cites this paper
• Léiomyosarcomes utérins localement avancés ou métastatiques : résultats de l’association doxorubicine, ifosfamide et cisplatine en traitement de première ligne

  2012cites this paper
• Nonendometrioid Endometrial Carcinomas and Uterine Sarcomas

  2012cites this paper
• Inhibition of Uterine Sarcoma Cell Growth through Suppression of Endogenous Tyrosine Kinase B Signaling

  2012cites this paper
• Advances in the systemic treatment of cutaneous sarcomas.

  2012cites this paper
• Targeted Therapies in Sarcomas: Challenging the Challenge

  2012cites this paper
• Novel VEGF-independent strategies targeting tumor vasculature: clinical aspects.

  2012cites this paper
• Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib.

  2011cites this paper
• Agent préventif et/ou remède pour le syndrome d'enflure douloureuse des mains et des pieds

  2011cites this paper
• Role of chemotherapy and biomolecular therapy in the treatment of uterine sarcomas.

  2011cites this paper
• Tumorangiogenese und aktuelle therapeutische Möglichkeiten der Inhibition

  2011cites this paper
• Uterine sarcomas--recent progress and future challenges.

  2011cites this paper
• Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years.

  2011cites this paper
• The Clinical Relevance of Molecular Genetics in Soft Tissue Sarcomas

  2010cites this paper
• Tyrosine kinase inhibitors in treating soft tissue sarcomas: sunitinib in non-GIST sarcomas

  2010cites this paper
• Optimal management of uterine leiomyosarcoma

  2010cites this paper